Interesting #ASH19 abstracts on CAR T cells:

Analysis of clonal dynamics in CAR T cell-treated patients suggests that long-term persisting clones originate primarily from infused T stem cell memory fraction #CARTcell
https://ash.confex.com/ash/2019/webprogram/Paper125916.html

More below (1/n):

Gamma-secretase inhibitor increases BCMA expression in CAR T cell-treated myeloma patients #ASH19 #CARTcell #mmsm
https://ash.confex.com/ash/2019/webprogram/Paper129405.html

Depletion of degron-tagged CARs using drug treatment (lenalidomide) as an off-switch to control toxicities #ASH19 #CARTcell
https://ash.confex.com/ash/2019/webprogram/Paper124210.html

High expression of CD57, Tbet, CD45RO, PD-1 predict response to CAR T cell therapy in DLBCL #ASH19 #CARTcell #lymsm
https://ash.confex.com/ash/2019/webprogram/Paper130815.html

Engineered CD28 subdomain mutations reduce CAR T cell exhaustion (in murine T cells) #ASH19 #CARTcell
https://ash.confex.com/ash/2019/webprogram/Paper131245.html

Shorter scFv linker improves CAR T cell activity #ASH19 #CARTcell
https://ash.confex.com/ash/2019/webprogram/Paper131024.html

Phase I study on anti-CD5 CAR T cells in T cell malignancies (3/9 complete responses) #ASH19 #CARTcell
https://ash.confex.com/ash/2019/webprogram/Paper129559.html